To date, three molecular targets (microsatellite instability-high (MSI-H) or mismatch repair deficient (MSI-H/dMMR), neurotrophic tropomyosin-related kinase (NTRK1/2/3) fusions or high tumor mutational burden (TMB-H)), have led to four site- or tumor-agnostic approvals by the FDA. This evidence concerns the gene NTRK1 and neoplasm.